8,833 Matching Annotations
  1. Dec 2021
    1. shinydoc. (2021, December 12). I love how I, an actual GP...who was involved in the initial covid vaccination programme ...has to tune in at 8pm with the public to find out that apparently we are vaccinating the entire adult population with boosters by the end of the year [Tweet]. @irishayesha. https://twitter.com/irishayesha/status/1470123478221303810

    1. Dave Keating. (2021, December 8). Boris Johnson’s continued pretence that UK is one of the most vaccinated countries in the world, repeated again in press conference just now announcing new restrictions, is getting tiresome. That has not been the case for many many months, despite 🇬🇧🇺🇸 vaccine hoarding early on. Https://t.co/tQt6aXGtNI [Tweet]. @DaveKeating. https://twitter.com/DaveKeating/status/1468655107436802052

    1. “In 2022, the fall out of the Covid-19 pandemic will continue to have an impact on manufacturing and the global supply chain. The long, erratic wait times will not go away anytime soon, especially as more variants emerge and potentially disrupt international travel and shipping routes. 
    1. Heitmann, J. S., Bilich, T., Tandler, C., Nelde, A., Maringer, Y., Marconato, M., Reusch, J., Jäger, S., Denk, M., Richter, M., Anton, L., Weber, L. M., Roerden, M., Bauer, J., Rieth, J., Wacker, M., Hörber, S., Peter, A., Meisner, C., … Walz, J. S. (2021). A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature, 1–9. https://doi.org/10.1038/s41586-021-04232-5

    1. mechanism responsible for blood clots arising from thrombosis with thrombocytopenia syndrome (TTS) following vaccination with AstraZeneca vaccine.

      covishield vaccine clotting problem

    1. Sean Phelan. (2021, November 26). Striking how some media coverage is assuming (without caveats) that the Belgian case brought the new variant “from” Egypt or Turkey.There’s no chance they picked it up after returning to Belgium of course. How could that happen..we only have a 7-day average of 17,000 cases a day [Tweet]. @seanphelan8. https://twitter.com/seanphelan8/status/1464252432033136659

    1. Seth Trueger. (2021, June 26). friendly reminder that “more transmissible” is by itself REALLY BAD for a pandemic. Even small increases in R₀ mean more potential for spread, more cases, more deaths etc please get your vax & help others get theirs https://t.co/mlojYmp71j [Tweet]. @MDaware. https://twitter.com/MDaware/status/1408811800108355586

    1. Art Poon. (2021, November 28). Our first https://filogeneti.ca/CoVizu update with B.1.1.529. As expected, number of mutations is well over molecular clock prediction (~13 diffs). Relatively low numbers of identical genomes implies large number of unsampled infections. We update every two days from GISAID. https://t.co/m8w2CjL1c0 [Tweet]. @art_poon. https://twitter.com/art_poon/status/1465001066194481162

    1. Eric Feigl-Ding. (2021, December 2). A rise in possible #Omicron in England—Tripling (0.1 to 0.3) of S-Gene dropout PCR signal, which is a proxy for Omicron (before 🧬 sequencing confirms). @_nickdavies estimates this represents around ~60 cases in 🏴󠁧󠁢󠁥󠁮󠁧󠁿. Still early—But it displacing #DeltaVariant is not good sign. 🧵 https://t.co/4aIiqiVsqH [Tweet]. @DrEricDing. https://twitter.com/DrEricDing/status/1466234026843205637

    1. nference. (2021, November 27). Here is how B.1.1.529 (#Omicron #B11529) compares to Alpha, Beta, Gamma, Delta variants. Omicron has highest novel Spike mutations including striking cluster on the “crown” suggesting significant selection pressure & antigenic distinction from prior strains (Credits: Nference) https://t.co/4oZQbjhbG8 [Tweet]. @_nference. https://twitter.com/_nference/status/1464404770098229250

    1. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Rathna Murugesan, D., Koundinya Desiraju, B., Kshetrapal, P., Pandey, R., Scaria, V., Kumar Malik, P., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., … Garg, P. K. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases, S1473309921006800. https://doi.org/10.1016/S1473-3099(21)00680-0

  2. Nov 2021
    1. Les responsables légaux des élèves devront attester sur l’honneur de la réalisation d’un test par l’élève et du résultat négatif de celui-ci
    1. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Murugesan, D. R., Desiraju, B. K., Kshetrapal, P., Pandey, R., Scaria, V., Malik, P. K., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., … Garg, P. K. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00680-0

    1. Stephen Reicher. (2021, November 26). 55.1% of the worlds population has had one dose of Covid vaccine. 29% in South Africa 10.1% in Africa as a whole Only 6% of Africans are fully vaccinated So is it any surprise new variants are arising from Africa? What doesn’t go around (as vaccine) Comes around (as Covid). Https://t.co/0X0vZ6flmc [Tweet]. @ReicherStephen. https://twitter.com/ReicherStephen/status/1464202267196858380

    1. trying to counter the antivaccine movement predicted that antivaxxers would publicize and weaponize reports of death and adverse events after COVID-19 vaccines to give the impression that the vaccines are dangerous

      That's ironic. That's exactly what the vaccine-pushers are doing: over-reporting the danger of the Covid virus.

    1. contrasting 00:28:28 climate change against uh the kobe 19 pandemic is very revealing while both of them are now considered to be a crisis and they are very different in nature 00:28:40 the pandemic is an immediate threat and the government failure to respond to the the kubernetes pandemic is in the eyes of the constituencies 00:28:54 a real failure and and they will uh lose their future votes and because of this failure for these politicians while climate change is more of a 00:29:07 creeping uh risks it's coming slowly it is a crisis and uh and it's also everybody's crisis right then this is a a typical 00:29:21 collective action problem failure to come up with the funding for addressing climate change in the eyes of the local and domestic 00:29:33 constituencies is not considered to be such a bad thing so uh and then a lot of politicians will choose to be a free writer on this then 00:29:45 uh you know what happens and we all understand this too well will be the tragedy of the comments i think the it's really the nature of the this uh two problems to crisis are very different 00:29:58 and this is really really the talent the i think the ultimate talent for the human beings to when it comes to solve this collective action problem

      The speaker points out that covid-19 is perceived as a more immediate threat, while climate change is less directly perceivable as a immediate threat. It takes place graduallyl over time. Climate change is a tragedy of the commons because a lot of individual leaders choose to free-ride.

    1. It remains unclear whether the reduction in the neutralization sensitivity of the N501Y.V2 strain to vaccine-induced antibodies is enough to seriously reduce vaccine efficacy. First, mRNA vaccines also induce virus-specific helper T cells and cytotoxic T cells, both of which might be involved in protection against challenge. Also, the mRNA vaccines, in particular, induce such a strong NAb response that there could be enough “spare capacity” to deal with reductions in the sensitivity of the variant to NAbs. In other words, N501Y.V2 (and the related virus from Brazil) may be less sensitive to NAbs, but not to an extent that will cause widespread vaccine failure.

      Variants that show reduced sensitivity to NAbs don't necessarily mean mRNA vaccine failure

      New variants may emerge that show reduced sensitivity to NAbs.

      This may not result in vaccine failure because:

      1. The mRNA vaccines induce such a strong NAb response, there will be enough spare capacity to deal with the virus.
      2. The mRNA vaccines also induce other virus specific protection such as helper T cells and cytotoxic T cells, which may not be affected by the reduction in NAb sensitivity.
    1. ReconfigBehSci. (2021, November 23). query: Https://unherd.com/2021/11/the-lefts-covid-failure/ “Is there really no progressive criticism to be made about the quarantining of healthy individuals, when the latest research suggests there is a vanishingly small difference in terms of transmission between the vaccinated and the unvaccinated?” 1/2 [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1463146737804140558

    1. Prof. Christina Pagel. (2021, November 24). Meanwhile AY.4.2 (Delta grandchild) continues its very slow path to English dominance. Makes life a bit harder by being a bit more transmissible but luckily doesn’t seem any worse than Delta in any other respect. Https://t.co/kB0V0Z66GT [Tweet]. @chrischirp. https://twitter.com/chrischirp/status/1463508172941967365

    1. Seth Trueger. (2021, July 21). If seatbelts work so well why do we have airbags crumple zones speed limits licensing road signs traffic lights road safety engineering ambulances EMTs trauma centers brakes https://t.co/6x29wCOlwp [Tweet]. @MDaware. https://twitter.com/MDaware/status/1417680529160294401

    1. The study demonstrated the capacity of a third dose to broaden antibody-based immunity and boost protection against circulating variants of concern. However, it is interesting that neutralizing responses against the Beta variant, known to markedly escape vaccine-elicited antibody responses4, were only fractionally better in those receiving a Beta-specific booster immunization.

      Choi et al. showed that a Beta-targeted booster shot broadened antibody-based immunity and boosted protection against circulating variants, the neutralizing response against the Beta variant was only slightly better.

      @gerdosi thinks this points to Original Antigenic Sin.

    1. Tania Bubela. (2021, November 17). New resources on #COVID19vaccines & #pregnancy from the fantastic group @CDCofBC Indigenous Knowledge Translation Working Group. @HarlanPruden working to meet knowledge needs of Indigenous communities in ways that are meaningful. @ScienceUpFirst take note! @SFU_FHS @CaulfieldTim https://t.co/oK3WJUj9p6 [Tweet]. @bubela_tania. https://twitter.com/bubela_tania/status/1460776956379557889

    1. COVID-19 Living Evidence. (2021, November 12). As of 12.11.2021, we have indexed 257,633 publications: 18,674 pre-prints 238,959 peer-reviewed publications Pre-prints: BioRxiv, MedRxiv Peer-reviewed: PubMed, EMBASE, PsycINFO https://t.co/ytOhLG90Pi [Tweet]. @evidencelive. https://twitter.com/evidencelive/status/1459163720450519042

    1. Jeffrey Barrett. (2021, October 19). Proportion of AY.4.2 (now on http://covid19.sanger.ac.uk) has been steadily increasing in England, which is a pattern that is quite different from other AY lineages. Several of them rose when there was still Alpha to displace, but none has had a consistent advantage vs other Delta. Https://t.co/mD5gQzKxgV [Tweet]. @jcbarret. https://twitter.com/jcbarret/status/1450408485829718039

    1. Prof. Christina Pagel. (2021, November 3). Good @NatGeo article by @Ecquis on the growing AY.4.2 variant in the UK with lots of great experts explaining it. And a little bit of me too! At its current growth rate, it will probably become dominant in UK by the end of the year. Https://t.co/X9O9kbew2L [Tweet]. @chrischirp. https://twitter.com/chrischirp/status/1455899379475361795

    1. Walter, E. B., Talaat, K. R., Sabharwal, C., Gurtman, A., Lockhart, S., Paulsen, G. C., Barnett, E. D., Muñoz, F. M., Maldonado, Y., Pahud, B. A., Domachowske, J. B., Simões, E. A. F., Sarwar, U. N., Kitchin, N., Cunliffe, L., Rojo, P., Kuchar, E., Rämet, M., Munjal, I., … Gruber, W. C. (2021). Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. New England Journal of Medicine, NEJMoa2116298. https://doi.org/10.1056/NEJMoa2116298